IRDHealthcare · BiotechnologyThe 18 Wall Street analysts covering Opus Genetics, Inc. hold a median 12-month price target of $13 — +256.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Opus Genetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (93): The shares have been drifting up relative to others.
Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on IRD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +256.2% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | Chardan Capital | Maintains | Buy | $16 |
| 16 Oct 2026 | Citizens | Reiterates | Market Outperform | $17 |
| 6 Oct 2026 | Jones Trading | Maintains | Buy | — |
| 2 Oct 2026 | Chardan Capital | Maintains | Buy | $16 |
| 2 Oct 2026 | Chardan Capital | Maintains | Buy | — |
| 10 Sept 2026 | Wedbush | Maintains | Outperform | — |
| 10 Sept 2026 | Wedbush | Maintains | Outperform | $10 → $13 |
| 9 Sept 2026 | BTIG | Reiterates | Buy | $12 |
| 9 Sept 2026 | BTIG | Reiterates | Buy | — |
| 9 Sept 2026 | Chardan Capital | Maintains | Buy | — |
| 9 Sept 2026 | Chardan Capital | Maintains | Buy | $13 → $16 |
| 9 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 9 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Sept 2026 | Oppenheimer | Maintains | Outperform | $10 → $20 |
| 9 Sept 2026 | Oppenheimer | Maintains | Outperform | — |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $10 → $9.00 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 29 July 2026 | TD Cowen | Initiates | Buy | — |
| 29 July 2026 | TD Cowen | Initiates | Buy | — |
| 6 July 2026 | BTIG | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IRD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Opus Genetics, Inc. returned +84.3% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 7% of US stocks
Cheaper than 99% of US stocks
Cheaper than 80% of US stocks
Higher than 3% of US stocks
Higher than 6% of US stocks
Higher than 4% of US stocks
Higher than 30% of US stocks
Higher than 1% of US stocks
Higher than 8% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Opus Genetics, Inc. has a market value of $287.9M and an enterprise value of $235.7M.
Revenue in the twelve months to 30 June 2026: $9.9M. The latest quarter shrank 73.8% year on year.
Net income over the same four quarters: −$107.6M, a −1091.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$40.7M.
Opus Genetics, Inc. spent $149K on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −4.3×; forward P/E: −4.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Opus Genetics, Inc. employs 27 people — $365K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Opus Genetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Opus Genetics announced the appointments of Andrew Murphy, Ph.D., as chief scientific officer and Jamie Lynne Hart as executive director, executive operations.
Why it matters — The appointments add two named leaders to the company developing gene therapies for inherited retinal diseases.
Opus Genetics outlined its commercialization expectations for its newly FDA-approved presbyopia eye drop, updates on its inherited retinal disease gene therapy pipeline, and funding strategy during an investor panel.
Why it matters — The discussion gives IRD watchers a company update on plans for the approved drop, pipeline progress, and funding approach.
Opus Genetics announced that the FDA cleared its IND application for OPGx-RDH12, an investigational gene therapy for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childhood. The company also cited a strategic collaboration with the Global RDH12 Alliance supporting development.
Why it matters — The clearance enables clinical development of a candidate targeting an inherited retinal disease associated with early childhood vision loss and high unmet need.
Opus Genetics announced FDA approval of its supplemental New Drug Application for phentolamine ophthalmic solution 0.75% to treat presbyopia in adults. The approval was supported by positive results from the Phase 3 VEGA-2 and VEGA-3 trials, which met their primary and all key secondary efficacy endpoints.
Why it matters — The FDA approval expands the approved use of an Opus Genetics product to include age-related near-vision impairment.
Opus Genetics presented clinical findings from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026. OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose cohort, while OPGx-LCA5 showed sustained visual acuity and light-sensitivity improvements through 24 months in adults and encouraging results in children through six months.
Why it matters — The update provides clinical data across two programs, and the company said Phase 3 dosing for OPGx-LCA5 is expected in the fourth quarter of 2026.
The 18 Wall Street analysts covering Opus Genetics, Inc. have a median 12-month price target of $13, with estimates ranging from $8 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Opus Genetics, Inc., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Opus Genetics, Inc. 55 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Opus Genetics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +256.2% from the last close, and Ticker Nerd's factor model ranks Opus Genetics, Inc. 55 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Opus Genetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $20 over the next 12 months.
Opus Genetics, Inc. returned +84.3% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations". Opus Genetics announced the appointments of Andrew Murphy, Ph.D., as chief scientific officer and Jamie Lynne Hart as executive director, executive operations.
Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies. The company develops gene therapies for inherited retinal diseases and additional small-molecule treatments for other eye disorders, including programs aimed at retinal degeneration, refractive conditions, and other vision-related diseases. Its current pipeline includes investigational candidates such as OPGx-LCA5 and OPGx-BEST1, along with other ophthalmology-focused programs targeting specific genetic retinal conditions. Opus Genetics serves the broader vision-care market through research, development, and commercialization efforts centered on restoring or preserving sight in patients with unmet medical needs. The company is headquartered in Durham, North Carolina.
CEO Dr. George Magrath M.B.A., M.D., M.S. · 27 employees · United States · https://opusgtx.com
